NT

Nikhil Teja Reddy Mandha

Active Director Director DIN 08655753
DIN 08655753 First appointment Dec 2019 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 6 active board seats
Total affiliations 6 Since Dec 2019
Shareholding value •••• Premium profile

About Nikhil Teja Reddy Mandha

Data last updated:

Nikhil Teja Reddy Mandha is a Director at Enal Drugs Pvt Ltd (since 2024), Director at Apichem Laboratories Private Limited (since 2020) and Director at Zen Distillation Technologies Private Limited (since 2025), and holds 3 more current directorships. The companies operate in Pharma, Chemicals and Materials and Chemicals. The 5 current companies with reported revenue have a combined latest revenue of ₹118 Cr; the largest is Enal Drugs Pvt Ltd at ₹55.27 Cr (FY 2024).

DIN 08655753
Primary Designation Director
Industry Pharma
First Appointment 31 Dec 2019
Oldest Company Age 36 yrs
Largest company Enal Drugs Pvt Ltd · ₹55.27 Cr (FY 2024)
Combined revenue ₹118 Cr across 5 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Enal Drugs Pvt Ltd U24230TG1990PTC011422
Director01 Feb 20241990₹55.27 Cr (FY 2024)Active
Apichem Laboratories Private Limited U24230TG2020PTC138207
Director06 Jan 20202020₹55.25 Cr (FY 2024)Active
Director10 Sep 20252010₹7.42 Cr (FY 2025)Active
Apiform Laboratories Private Limited U24239TG2019PTC138106
Director31 Dec 20192019₹2 Lakh (FY 2024)Active
Organozen Chemicals Private Limited U24100TG2020PTC141849
Director10 Sep 20252020₹20,795 (FY 2025)Active
Director29 Apr 20252025Active

Directorship timeline

Open interactive timeline →
Apichem Laboratories Private Limited
Apiform Laboratories Private Limited
Organozen Chemicals Private Limited
S V Pharma Analytical Services Private Limited
Premium access

Shareholding and investment profile for Nikhil Teja Reddy Mandha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nikhil Teja Reddy Mandha

Nikhil Teja Reddy Mandha currently holds 6 directorships: Enal Drugs Pvt Ltd (Director, since 01 Feb 2024, revenue ₹55.27 Cr (FY 2024)); Apichem Laboratories Private Limited (Director, since 06 Jan 2020, revenue ₹55.25 Cr (FY 2024)); Zen Distillation Technologies Private Limited (Director, since 10 Sep 2025, revenue ₹7.42 Cr (FY 2025)); Apiform Laboratories Private Limited (Director, since 31 Dec 2019, revenue ₹2 Lakh (FY 2024)); Organozen Chemicals Private Limited (Director, since 10 Sep 2025, revenue ₹20,795 (FY 2025)); and 1 more.

Nikhil Teja Reddy Mandha was first appointed on 31 Dec 2019 as Director at Apiform Laboratories Private Limited. The most recent appointment on record is 10 Sep 2025 at Organozen Chemicals Private Limited.

The 5 current companies of Nikhil Teja Reddy Mandha that report revenue have a combined latest revenue of ₹118 Cr: Enal Drugs Pvt Ltd ₹55.27 Cr (FY 2024); Apichem Laboratories Private Limited ₹55.25 Cr (FY 2024); Zen Distillation Technologies Private Limited ₹7.42 Cr (FY 2025); Apiform Laboratories Private Limited ₹2 Lakh (FY 2024); Organozen Chemicals Private Limited ₹20,795 (FY 2025).

The current boards of Nikhil Teja Reddy Mandha's companies include Achyuth Reddy Manne (Enal Drugs Pvt Ltd), Suresh Babu Sunkaraneni (Enal Drugs Pvt Ltd), Uma Sunkaraneni (Enal Drugs Pvt Ltd), Birendra Kumar Nath (Apichem Laboratories Private Limited), Pooja Reddy Konda Reddy (Zen Distillation Technologies Private Limited), Sindhuja Reddy Manne (S V Pharma Analytical Services Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available